CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new trea...
Phase 2
London, United Kingdom and 24 other locations
multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...
Phase 2
Sutton, United Kingdom and 16 other locations
with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy.All patients will rec...
Phase 2
London, United Kingdom and 32 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Sutton, United Kingdom and 50 other locations
TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess...
Phase 2
London, United Kingdom and 47 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
London, United Kingdom and 26 other locations
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...
Phase 2
London, United Kingdom and 59 other locations
dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...
Phase 1, Phase 2
London, United Kingdom and 104 other locations
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...
Phase 2
London, United Kingdom and 93 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
London, United Kingdom and 66 other locations
Clinical trials
Research sites
Resources
Legal